Syra Health Corp (SYRA) Form S-1 — Sep 14, 2026
Syra Health Corp filed an S-1 to register for resale up to 3,171,100 Class A shares issuable upon exercise of Series B warrants originally issued September 13, 2024 in a registered direct offering. Each warrant is exercisable at $0.64 per share and expires September 13, 2029. The company receives no proceeds from the selling stockholders' sales; it would collect approximately $2.03 million gross only if the warrants are exercised for cash. Class A shares closed at $0.91 on the OTCQB on September 10, 2026, after the company was delisted from Nasdaq in April 2025.
Key figures
- Revenue
- $7,225,973 (FY2025); $7,982,082 (FY2024); ~$4.7M (six months ended 6/30/2026)
- Net Income
- -$896,333 (FY2025); -$3,759,238 (FY2024); +$491,221 (six months ended 6/30/2026)
- Revenue Yoy
- -9% (FY2025 vs FY2024, a decrease of $756,109)
- Cash Position
- 2123747
- Gross Proceeds
- ~$2,029,504 to the company only upon full cash exercise of Series B Warrants
- Offering Price
- 0.64
- Shares Offered
- 3171100
- Shares Outstanding
- 13,839,169 Class A and 350,000 Class B (as of 6/30/2026)
- Dilution overhang
- ~23% of Class A shares outstanding (3,171,100 registered on 13,839,169, calculated)
- Warrant expiration
- September 13, 2029
- Accumulated deficit
- $9,229,305 as of 6/30/2026
- Stockholders equity
- $2,758,838 as of 6/30/2026
- Nasdaq delisting date
- on or about April 11, 2025
- Customer concentration
- Humana ~37% of revenue (FY2025 and 6M 2026); FSSA 35% of FY2025 revenue and 18% of 6M 2026 revenue
- Stock price 2026 09 10
- $0.91 (OTCQB close)
- Warrant exercise price
- $0.64 per Series B Warrant
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.